Phenotypes Associated with This Genotype

Genotype
MGI:5633962

• Allelic Composition: Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
• Genetic Background: involves: FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

endocrine/exocrine glands

prostate gland hyperplasia ( J:184212 , J:206727 )

♂ • treatment with with a chemical inducer of dimerization, AP20187, for up to 20 weeks results in a modest hyperproliferation of prostate epithelial cells, high proliferative rates in both ventral and dorsal lobes, development of luminal hyperplasia, and modest stromal thickening (J:184212)

♂ • treatment with AP20187 beyond 20 weeks results in more prominent hyperproliferation in the ventral and dorsal prostate lobes and acinar disorganization (J:184212)

♂ (J:206727)

increased prostate gland adenocarcinoma incidence ( J:184212 , J:206727 )

♂ • after 52 weeks of treatment with a chemical inducer of dimerization, AP20187, 2 of 6 male mice develop prostate tumor, with progression over several months from prostate hyperplasia to adenocarcinoma (J:184212)

♂ (J:206727)

reproductive system

prostate gland hyperplasia ( J:184212 , J:206727 )

♂ • treatment with with a chemical inducer of dimerization, AP20187, for up to 20 weeks results in a modest hyperproliferation of prostate epithelial cells, high proliferative rates in both ventral and dorsal lobes, development of luminal hyperplasia, and modest stromal thickening (J:184212)

♂ • treatment with AP20187 beyond 20 weeks results in more prominent hyperproliferation in the ventral and dorsal prostate lobes and acinar disorganization (J:184212)

♂ (J:206727)

increased prostate gland adenocarcinoma incidence ( J:184212 , J:206727 )

♂ • after 52 weeks of treatment with a chemical inducer of dimerization, AP20187, 2 of 6 male mice develop prostate tumor, with progression over several months from prostate hyperplasia to adenocarcinoma (J:184212)

♂ (J:206727)

neoplasm

increased prostate gland adenocarcinoma incidence ( J:184212 , J:206727 )

♂ • after 52 weeks of treatment with a chemical inducer of dimerization, AP20187, 2 of 6 male mice develop prostate tumor, with progression over several months from prostate hyperplasia to adenocarcinoma (J:184212)

♂ (J:206727)